| mediator of acute inflammation | | |
| mediator of chronic inflammation | | |
| cell type: source for the chronic inflammation mediator TNF alpha | | |
| Primary Effect of TNF alpha in chronic inflammation: | | |
| may slow bone damage associated with rheumatoid arthritis | | |
| reduces pharmacological activity of spironolactone, competes with penicillin G. for renal tubular secretion;inhibits probenecid uricosuric effect | | |
| celecoxib | | |
| salicylate, but less effective than aspirin as cyclooxygenase inhibitors | | |
| transaminitis (increase serum aminotransferase) | | |
| infusion of this drug: accelerates closure of patent ductus arteriosus in premature newborns | | |